Literature DB >> 21181458

Special issues in myeloproliferative neoplasms.

Tiziano Barbui1, Guido Finazzi.   

Abstract

Special issues in myeloproliferative neoplasms (MPN) comprise clinical conditions with high relevance for the duration and quality of the patient's life, but with limited evidence to support sound diagnostic and therapeutic recommendations and a low probability of being solved by the current standard of clinical research. These issues include MPN in pregnancy and in children, abdominal vein thrombosis, bleeding complications, surgery, pruritus, and leukemic transformation. Practical suggestions to guide clinical decisions in these settings remain largely empirical, but recently developed guidelines based on experts' consensus may help to tackle these problems. This article reviews the state of the art regarding these issues, with special emphasis on experts' consensus recommendations.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21181458     DOI： 10.1007/s11899-010-0073-7

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN： 1558-8211            Impact factor:   3.952


  45 in total

Review 1.  Primary and secondary thrombocytosis in childhood.

Authors:  Christof Dame; Anton Heinz Sutor
Journal:  Br J Haematol       Date:  2005-04       Impact factor: 6.998

2.  Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients.

Authors:  N Gangat; A P Wolanskyj; R F McClure; C-Y Li; S Schwager; W Wu; A Tefferi
Journal:  Leukemia       Date:  2006-12-14       Impact factor: 11.528

3.  Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome.

Authors:  Raj K Patel; Nicholas C Lea; Michael A Heneghan; Nigel B Westwood; Dragana Milojkovic; Murugaiyan Thanigaikumar; Deborah Yallop; Roopen Arya; Antonio Pagliuca; Joop Gäken; Julia Wendon; Nigel D Heaton; Ghulam J Mufti
Journal:  Gastroenterology       Date:  2006-06       Impact factor: 22.682

4.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.

Authors:  Srdan Verstovsek; Hagop Kantarjian; Ruben A Mesa; Animesh D Pardanani; Jorge Cortes-Franco; Deborah A Thomas; Zeev Estrov; Jordan S Fridman; Edward C Bradley; Susan Erickson-Viitanen; Kris Vaddi; Richard Levy; Ayalew Tefferi
Journal:  N Engl J Med       Date:  2010-09-16       Impact factor: 91.245

5.  Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis.

Authors:  Yasmine Chait; Bertrand Condat; Dominique Cazals-Hatem; Pierre Rufat; Sai Atmani; Driss Chaoui; Françoise Guilmin; Jean Jacques Kiladjian; Aurélie Plessier; Marie Hélène Denninger; Nicole Casadevall; Dominique Valla; Jean B Brière
Journal:  Br J Haematol       Date:  2005-05       Impact factor: 6.998

6.  Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis.

Authors:  S Cortelazzo; G Finazzi; M Ruggeri; O Vestri; M Galli; F Rodeghiero; T Barbui
Journal:  N Engl J Med       Date:  1995-04-27       Impact factor: 91.245

Review 7.  The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?

Authors:  Tiziano Barbui
Journal:  Semin Hematol       Date:  2004-04       Impact factor: 3.851

8.  Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.

Authors:  Ayalew Tefferi; Juergen Thiele; Attilio Orazi; Hans Michael Kvasnicka; Tiziano Barbui; Curtis A Hanson; Giovanni Barosi; Srdan Verstovsek; Gunnar Birgegard; Ruben Mesa; John T Reilly; Heinz Gisslinger; Alessandro M Vannucchi; Francisco Cervantes; Guido Finazzi; Ronald Hoffman; D Gary Gilliland; Clara D Bloomfield; James W Vardiman
Journal:  Blood       Date:  2007-05-08       Impact factor: 22.113

Review 9.  Thrombocythaemia and pregnancy.

Authors:  Michelle A Elliott; Ayalew Tefferi
Journal:  Best Pract Res Clin Haematol       Date:  2003-06       Impact factor: 3.020

10.  Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies.

Authors:  Naseema Gangat; Alexandra P Wolanskyj; Susan Schwager; Ayalew Tefferi
Journal:  Eur J Haematol       Date:  2009-01-06       Impact factor: 2.997
View more
  3 in total

1.  Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.

Authors:  M B Agarwal; Hemant Malhotra; Prantar Chakrabarti; Neelam Varma; Vikram Mathews; Jina Bhattacharyya; Tulika Seth; K Gayathri; Hari Menon; P G Subramanian; Ajay Sharma; Maitreyee Bhattacharyya; Jay Mehta; A K Vaid; Sandeep Shah; Shyam Aggarwal; P K Gogoi; Reena Nair; Usha Agarwal; Subhash Varma; S V S S Prasad; Marie Therese Manipadam
Journal:  Indian J Med Paediatr Oncol       Date:  2015 Jan-Mar

Review 2.  Hematologic malignancies during pregnancy: A review.

Authors:  Hossam K Mahmoud; Mohamed A Samra; Gamal M Fathy
Journal:  J Adv Res       Date:  2016-02-08       Impact factor: 10.479

3.  A case of Philadelphia chromosome positive myeloproliferative neoplasm in a pregnant woman with unusual primary myelofibrosis features.

Authors:  Jason Koshy; Jack Alperin; Bagi Jana; Avi Markowitz; You-Wen Qian
Journal:  Case Rep Hematol       Date:  2013-05-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.